Infinity Pharmaceuticals, Inc.
INFIQ · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $2,593 | $1,858 | $1,719 | $3,049 |
| % Growth | 39.6% | 8.1% | -43.6% | – |
| Cost of Goods Sold | $1,563 | $1,120 | $1,037 | $7,308 |
| Gross Profit | $1,030 | $738 | $682 | -$4,259 |
| % Margin | 39.7% | 39.7% | 39.7% | -139.7% |
| R&D Expenses | $32,411 | $31,647 | $26,761 | $27,116 |
| G&A Expenses | $13,463 | $14,174 | $12,418 | $14,289 |
| SG&A Expenses | $13,463 | $14,174 | $12,418 | $14,289 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $45,874 | $45,821 | $39,179 | $41,405 |
| Operating Income | -$44,844 | -$45,083 | -$38,497 | -$45,664 |
| % Margin | -1,729.4% | -2,426.4% | -2,239.5% | -1,497.7% |
| Other Income/Exp. Net | $475 | -$179 | -$1,995 | -$1,447 |
| Pre-Tax Income | -$44,369 | -$45,262 | -$40,492 | -$47,111 |
| Tax Expense | $0 | $0 | $0 | -$54 |
| Net Income | -$44,369 | -$45,262 | -$40,492 | -$47,057 |
| % Margin | -1,711.1% | -2,436.1% | -2,355.6% | -1,543.4% |
| EPS | -0.5 | -0.53 | -0.68 | -0.83 |
| % Growth | 5.7% | 22.1% | 18.1% | – |
| EPS Diluted | -0.5 | -0.53 | -0.68 | -0.83 |
| Weighted Avg Shares Out | 89,248 | 85,597 | 59,858 | 56,984 |
| Weighted Avg Shares Out Dil | 89,248 | 85,597 | 59,858 | 56,984 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $180 | $180 | $2,445 | $2,563 |
| Depreciation & Amortization | $458 | $480 | $483 | $219 |
| EBITDA | -$43,731 | -$44,602 | -$37,564 | -$44,329 |
| % Margin | -1,686.5% | -2,400.5% | -2,185.2% | -1,453.9% |